Skip to the content
ClearNote Health logologo darklogo light
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
Search
ClearNote Health logo
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
ClearNote Health logo
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
Home2024(Page 2)
Event

Digestive Disease Week | May 18th – 21st, 2024

cnhnewcorpdev
May 2, 2024
Detection of High-Risk Pancreatic Cysts using Avantect™ blood-based test
Event

American Medical Association CPT Editorial Panel Meeting | May 9th – 11th, 2024

cnhnewcorpdev
May 1, 2024
Event

CMS Public Meeting on New and Reconsidered Clinical Diagnostic and Laboratory Test Codes | June 25th, 2024

cnhnewcorpdev
May 1, 2024
Event

American Association for Cancer Research | April, 2024

cnhnewcorpdev
April 1, 2024
Press Release

New Data Show ClearNote Health’s Epigenomic Platform Provides a Novel Tissue-Free, Liquid Biopsy-Based Approach to Identify Potential Predictive Biomarker Candidates to Radioligand Therapy Response in Patients With Pancreatic Neuroendocrine Tumors

ClearNote Health
March 26, 2024
Event

Precision Med TRI-CON | March, 2024

cnhnewcorpdev
March 3, 2024
Event

European Neuroendocrine Tumor Society | March, 2024

cnhnewcorpdev
March 1, 2024
Event

Circulating Nucleic Acids in Plasma Symposium | March, 2024

cnhnewcorpdev
March 1, 2024
Press Release

Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology

ClearNote Health
January 30, 2024

Posts pagination

1 2 3

ClearNote Health Announces Leadership Transition

ClearNote Health
July 9, 2026

Meet Us at ASCO 2026

ClearNote Health
May 28, 2026

Follow us
ClearNote Health logo

Empowering early cancer detection.

Order Test
Company
  • About Us
  • Leadership Team
  • Our News
  • Careers
  • Contact Us
Solutions
  • Avantect Pancreatic Cancer Test
  • Avantect Ovarian Cancer Test
  • Virtuoso Epigenomics Platform
Stay Informed

Get the latest research and announcements from ClearNote Health. Follow us:

Important information: 
The Virtuoso platform is for research use only. Not for use in diagnostic procedures. The Avantect Pancreatic and Ovarian Cancers Tests are early detection tests. The tests do not establish a diagnosis of pancreatic cancer or ovarian cancer, respectively, and results should be considered in the context of other clinical criteria.

Cancer statistics quoted on this website are taken from the CDC and SEER websites, 2025 data.

©2026 ClearNote Health, All Rights Reserved.

Avantect and Virtuoso are trademarks of ClearNote Health. Other trademarks are the property of their respective owners.

  • Privacy Policy
  • Terms of Use
  • Billing rights & protections
  • Cookie Preferences